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that is possible to achieve cost-savings and a potential clinical benefit with the 
fixed dose of IG for Mexican patients with COPD.
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Objectives: To analyze ambulatory prescribing practice and to assess the cost-
effectiveness of asthma pharmacotherapy in country settings. MethOds: It is a 
prospective prescribing practice and cost-effectiveness analysis. During 2008-2011 
were observed 238 patients in Plovdiv region and collected information about their 
ambulatory asthma pharmacotherapy. Prescribed medicines were systematized in 
INN groups of mono and fixed dose combination products. The FEO1 and percentage 
of patients without exacerbation were used as measure of the therapeutic results. 
Incremental cost-effectiveness ratio was calculated and with Tornado diagram was 
explored the sensitivity of the results. Results: Pharmacotherapy with fixed dose 
combination was performed mainly with Beclomethazone/formoterol; Budesonide/
formoterol; and Salmeterol/fluticasone. The monthly cost of pharmacotherapy is 
varying among 35 and 50 Euro. Incremental cost effectiveness ratio is favoring the 
combination Beclomethazone/ formoterol 100/6 mcg with ICER of 324 Euro for addi-
tional increase in FEO1, and 50 Euro ICER for additional patient without exacerba-
tion, although all alternatives are cost-effective because all ICERs fall below the GDP 
per capita. The monotherapy was performed with Beclomethazone, Fluticasone, 
Budesonide, Ciclesonide, and Montelukast. Its monthly cost was among 19 and 40 
Euro. Incremental cost effectiveness ratio is favoring ciclesonide that is a dominant 
alternative as monotherapy for both studies outcomes. Results are sensitive to the 
changes in therapeutic outcomes. cOnclusiOns: The real life therapy follows the 
international guidelines but less fixed dose combinations were prescribed in com-
parison with international recommendations. Beclomethazone/ formoterol fixed 
dose combination and ciclesonide as monotherapy are cost-effective alternatives 
for the observed health care settings.
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Objectives: Study of clinical efficacy, tolerance and economic indicators of treat-
ment of non-severe CAP by (5-day) course of levofloxacin 750 mg/day vs. the stand-
ard administration of levofloxacin 500 mg/day. MethOds: The research included 64 
patients having non-severe CAP with risk factors (administration of antibiotics during 
the preceding 3 months, concomitant diseases), all of them being males. The patients 
were randomized into 2 groups; the 1st group received high-dose therapy of levofloxa-
cin, 750 mg/day within 5 days (Remedia, Simpex-Pharma, India). 2nd group recieved 
levofloxacin 500 mg/day for 7-10 days (Tavanic®, Sanofi-Winthrop Ind.). Efficacy and 
safety were assessed in terms of comprehensive analysis of clinical, laboratory and 
radiological data. For economic analysis, direct medical costs and “costs-efficacy” 
ratios (CER) were calculated. Results: First group included 32 patients with aver-
age age 22.7±1.8 years. Second group consisted of 32 patients with average 21.8±6 
years. Clinical efficacy of high-dose levofloxacin therapy amounted to 96.9%. Average 
duration of antibiotic treatment was 5.2±0.9 days.. Standard regime by levofloxacin 
was efficient in 100% of cases. Radiological resolution was identical in both groups. 
Transient increase of hepatic transaminase activity was present in 3 patients (9.4%). 
In standard group, this adverse event was present in 4 patients (12.5%). Average treat-
ment cost by levofloxacin 750 mg/day amounted to 13.3±6.2 euros (CERLEVO-750= 13.7); 
cost of the standard therapy was 27.2±4.9 euros (CERLEVO-750= 27.2). cOnclusiOns
: Therefore, in terms of clinical efficacy and safety, the high-dose therapy (750 mg/
day) by levofloxacin, in brief course of treatment of patients having non-severe CAP, 
is comparable with the standard regime of treatment (levofloxacin 500 mg/day for 7 
to 10 days); and, is more efficient in economic terms.
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Objectives: Optimal asthma control has been associated with significant reduc-
tions in mortality, morbidity, and quality of life gains for the patients. Hospital 
Asthma Clinics (ACs) are hospital-based units run by an experienced team com-
posed of a pneumologist and a specialized nurse. Their aim is to provide effective 
treatment and optimal control to asthma patients. However, their impact on dis-
ease control and their cost-effectiveness are unknown. The objective of this study 
is to assess the cost-effectiveness of managing asthma patients in an AC versus 
traditional management. MethOds: We designed a case-crossover study using the 
medical records of all patients submitted to one AC in Spain during 2012. We defined 
the case period as 365 days after the first visit to the AC, and the control period as 365 
days before the index date. We calculated changes in relevant disease control indica-
tors and estimated the Incremental Cost Effectiveness Ratio (ICER) for one additional 
controlled patient. Results: The percentage of controlled patients increased from 
41% to 86% (n= 83, mean age was 49 ± 15.2; 66% female). Asthma control test score 
increased from 18.7 ± 4.6 to 22.6 ± 2.3 (p< 0.005), exacerbations decreased by 75% 
(p< 0.005) and FEV1 increased from 81.4% ± 17.5 to 84.4% ± 16.6 (p< 0.05). The use of 
ICS/LABA combinations decreased from 79.5% to 41%. On the contrary, the use of 
other drugs increased: anticholinergics from 3.6% to 16.9%, inhaled corticosteroids 
Objectives: Asthma is a chronic disorder requires continuous and long term man-
agement. Thus it makes the patient economically week and produces more burden 
on patient. Short acting β 2agonists in pressurized metered dose inhalers and dry 
powdered inhalers are the most commonly prescribed formulations in south Indian 
clinical settings. The present study aims to investigate and to select appropriate 
cost effective formulation of metered dose inhalers (MDR) or dry powdered inhalers 
(DPI) for salbutamol. MethOds: It is a prospective comparative study conducted 
among subjects those who were newly diagnosed with asthma. The patients were 
divided into two groups based on the type of inhaler used such as MDI or DPI group. 
All the patients were counseled about the usage of inhalers during their treat-
ment device allotment. Quality of life and FEV 1 were measured at the baseline 
visit. In addition to that data related to direct cost such as medical, laboratory and 
re- hospitalization costs were also measured at baseline. Follow up was done for 
both the groups. Similar to baseline visit quality of life, FEV1 and direct medical costs 
were measured during follow up. Results: The present study results shows that 
there is no significant difference between two groups with regards to demographic 
characteristics. We observed a significant difference in QOL (p < 0.05) and the mean 
score for two treatment devices groups was found to be 55.63 &43.72 respectively. 
There is no significant difference in FEV 1 (p > 0.05) and symptom free days between 
two treatment devices. Average cost effectiveness ratio was calculated and average 
cost effectiveness ratio for MDI were found to be less compared to DPI but statisti-
cally not significant. cOnclusiOns: Overall it was found that efficacy was higher 
in MDI than DPI and cost was equal for both the groups to treat newly diagnosed 
asthma patients with salbutamol.
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Objectives: To evaluate clinical efficacy, safety and cost-effectiveness of treat-
ment options for mild to moderate community-acquired pneumonia in patients 
with risk factors of poor efficacy (prior administration of antibiotics, comorbidi-
ties), comparing generic levofloxacin (Glevo, Glenmark Pharmaceuticals Ltd.) 
versus original levofloxacin (Tavanic®, Sanofi-Winthrop Ind.) and conventional 
treatment (b-lactam±macrolide). MethOds: Patients were randomized to 3 treat-
ment arms. Mean age was 24.3±11.5years. Treatment arm 1 included 61 patient 
administered GLEVO in the dose of 500 mg/day, whereas in the treatment arm 
2 (n= 41) patients were treated with original levofloxacin (Tavanic) in the dose 
of 500mg/day, and 45 patients in the treatment arm 3 received conventional 
therapy. Clinical efficacy and safety were evaluated based on clinical, laboratory 
and radiological data analysis. Cost-effectiveness analysis included calcula-
tion of direct medical expenses and cost-effectiveness ratios (CER). Results: 
Clinical efficacy rate in the treatment arm 1 (Glevo) was98.4%, in the treatment 
arm 2 (Tavanic)–97.6%, whereas conventional therapy efficacy rate was84.4%. 
Adverse event incidence in the treatment arm 1 was 21.3%, in treatment arms 2 
and 3 –14.6% and35.5% respectively. Treatment duration in the Glevo treatment 
arm was8.2±1.4days, in the treatment arm2 –8±1.2, in the conventional therapy 
arm–7.2±2,1 days. Time to radiological resolution of pneumonia was compa-
rable. Mean cost of antibiotic administration cycle and the cost-effectiveness 
ratio in patients administered Glevo was 7.65€ (CERGLEVO = 7.8), in the treatment 
arm 2 – 22.4€ (CERTAV= 22.9), in the conventional therapy arm–10.8€ (CERSTAND= 
12.8). cOnclusiOns: Administration of levofloxacin for mild to moderate com-
munity-acquired pneumonia in patients with risk factors is superior in clinical 
efficacy compared to conventional treatment modalities. Administration of Glevo 
is characterized by favorable cost-effectiveness parameters.
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Objectives: To perform a cost-effectiveness analysis of Indacaterol/
Glycopyrronium (IG) against tiotropium monotherapy (TM), salmeterol/flutica-
sone (SF) and indacaterol/tiotropium (IT) for COPD patients from the perspective 
of the Mexican Public Healthcare System. MethOds: A patient-simulation model 
structured in MS Excel, developed and validated by Asukai et al (2013), allowed us 
to compare IG against tiotropium monotherapy (TM), salmeterol/fluticasone (SF) 
and indacaterol/tiotropium (IT). The effectiveness measures analyzed were life 
years gained and exacerbations avoided based on efficacy data extracted from a 
comprehensive large phase III trial program comprising 11 studies (ILLUMINATE, 
SHINE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, ARISE, BEACON, RADIATE, LANTERN, 
FLAME) with more than 10,000 patients across 52 countries. COPD drug cost, main-
tenance cost and exacerbation cost were estimated for six months duration of 
model cycle, using local prices for public health care institutions and evaluating 
the resources utilization data extracted from a sample of medical records. Lifetime 
horizon was used and a discount rate of 5%. Deterministic and probabilistic sen-
sitivity analysis was performed. Results: Total expected costs per patient were 
US$30,421 and US$31,577 for the comparison IG vs TM respectively; US$28,817 and 
US$28,852 for IG vs SF respectively; US$28,900 and US$34,557 for IG vs IT respec-
tively. IG delivers slightly more life years than comparators, but avoid significantly 
more exacerbations than the other options (1 to 4) which in turn have favorable 
economic impacts. Sensitivity analysis showed that base-case results are robust to 
variations of key model parameters. cOnclusiOns: Indacaterol/ Glycopyrronium 
resulted more effective and less costly than comparators. These results showed 
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Hospitals (ATIH). Costs and outcomes were discounted at 4% through 30 years and 
2% thereafter. Robustness of results was assessed using sensitivity analyses. The 
assessed outcomes were the incremental cost per quality-adjusted life-year (QALY) 
gained and total life-years gained (LYG). Results: This study will inform public 
decision making about reimbursement of mild-to-moderate OSAHS treatments. 
CPAP was associated with higher costs and QALYs compared with dental devices, 
lifestyle advice and no treatment. Several sensitivity analyses were undertaken 
and it was found that the most sensitive parameters were related to sleepiness and 
cardiovascular inputs. Further investigation (clinical trial/observational study) of 
treatment effects on these parameters is needed. cOnclusiOns: This analysis is 
the first to assess the cost-effectiveness of treatments in mild-to-moderate OSAHS 
patients in France. The technical report of this research will be available on the 
HAS website at the time of the congress (November 2014).
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Objectives: Allergic rhinitis – hay fever and mite hypersensitivity - is a prevalent 
and increasingly common condition, causing considerable morbidity and eco-
nomic burden to society. A minority of patients have an indication for subcutane-
ous immunotherapy (SCIT). SCIT using extracts of tree pollen, grass pollen and/or 
house dust mite is common practice in The Netherlands, Europe and beyond. SCIT 
is widely reimbursed, but very few prospective cost-effectiveness studies have been 
done. MethOds: An open-label, 2-year, multicenter, randomized controlled trial 
with two parallel treatment arms was performed, comparing SCIT + usual care (UC) 
with UC alone, using online resource use and labor productivity questionnaires, and 
electronic versions of EQ-5D®, SF-36® and a global subjective assessment of symp-
toms (GA). Primary endpoints were the costs per QALY, costs per successfully treated 
patient and the cost per additional symptom-free day. A Generalized Estimation 
Equation (GEE) model was estimated with mean two-week health care/societal costs 
as dependent variable, followed by a 1000-iteration bootstrap procedure. Results: 
A total of 183 adult patients aged 18 to 45 years with persistent moderate to severe 
allergic rhinitis due to one (43%) or more (57%) allergies (93 SCIT+UC, 90 UC) were 
included. There were no significant differences at baseline. The percentage of 
patients that reported to be treated successfully was 36% in SCIT and 20% in UC 
after two years. Other health outcomes did not differ between SCIT and Usual Care. 
Two-year costs of SCIT were 2946 Euro per patient. There was no difference in other 
costs. Cost per additional successfully treated patient were about 15,000 Euro. For 
the other outcomes, SCIT was dominated by UC. cOnclusiOns: This study could 
not support the cost-effectiveness of SCIT. A restriction in the indication of SCIT 
to patients with severe persistent rhinitis, not sufficiently responsive to maximum 
symptomatic therapy may improve cost-effectiveness.
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Objectives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Alutard® or symptomatic drug treatment (SDT) on clinical effects and health care 
costs in subgroups of adults and children with grass pollen-induced allergic rhinitis 
(AR) in Germany. The cost-effectiveness of Oralair® has been demonstrated in a 
mixed population in previous research. MethOds: The effects of three years of drug 
treatment on quality-adjusted life years (QALYs) and associated costs were assessed 
using a Markov model with a nine-year time horizon. Symptom score data were 
extracted, and the relative efficacy on QALYs was assessed through a network meta-
analysis (i. e. indirect comparison) of placebo-controlled, clinical trial data in adults 
and children. Patient symptom scores were translated into the impact on quality of 
life by means of published sources. Costs associated with drug treatment and other 
health care resources, including Statutory Health Insurance payments and patient 
co-payments, were estimated. The incremental costs and QALYs were generated 
accordingly. The uncertainty around the model outcomes was determined by means 
of sensitivity analyses. Results: In adults, the analysis predicted more QALYs for 
Oralair® relative to Grazax®, 0.008 (95%CI: -0.043; 0.062) and Alutard®, 0.028 (95%CI: 
-0.029; 0.093), combined with incremental costs of -€ 1,272 (95%CI: -€ 1,530; -€ 999) 
and -€ 129 (95%CI: -€ 389; € 160) per patient, respectively. Hence, Oralair is dominant 
relative to Grazax® and Alutard® in adults. The incremental cost-effectiveness ratio 
was estimated at € 15,503 per QALY relative to SDT. Similar results were observed 
in children, with the exception of Alutard® (lack of data). The sensitivity analyses 
suggest that results were mostly driven by drug-specific clinical effects on symptom 
score, drug costs, inputs for immunotherapy discontinuation, and length of the pol-
len season. cOnclusiOns: Oralair® is cost-effective relative to Grazax®, Alutard® 
and SDT in grass pollen-induced AR in Germany. Findings were confirmed again 
and supported by extensive sensitivity analyses.
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alone from 3.6% to 45.8%, and omalizumab from 0% to 6%. Annual hospitalizations 
rates and emergency visits decreased by 78% and 75% respectively. The ICER was 
1800€ per controlled patient per year. cOnclusiOns: Managing asthma patients 
in a specialized AC is cost-effective and has significant impact on patient control, 
indicating better survival and quality of life for the patient according to published 
literature evidence.
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Objectives: A health economic assessment was conducted to determine the 
relative impact of treatment with Oralair® or Grazax® on clinical effects and 
health care costs in patients with grass pollen-induced allergic rhinitis (AR) in 
Germany. MethOds: The effects of three years of drug treatment on symptom-
free days (SFDs) and associated costs were assessed using a health economic 
Markov model with a nine-year time horizon. The relative efficacy on SFDs was 
assessed through a network meta-analysis (i. e. indirect comparison) of 4-year, 
placebo-controlled, clinical trial data. Costs associated with drug treatment and 
other health care resources, including Statutory Health Insurance payments and 
patient co-payments, were calculated. The incremental costs and SFDs gained for 
Oralair® relative to Grazax® were generated accordingly. The uncertainty around 
the model outcomes was determined by means of sensitivity analyses. Results: 
The base case analysis over 9 years predicts a total of 206.6 discounted SFDs for 
Oralair®relative to 205.1 for Grazax®, thus resulting in 1.5 (95%CI: -25.0; 29.3) addi-
tional SFDs gained with Oralair®. Total discounted costs are estimated at € 1,696 and 
€ 2,968 for Oralair® and Grazax®, respectively, with incremental costs predicted at 
-€ 1,272 (95%CI: -€ 1,530; -€ 999). Hence, Oralair® may be classified as the dominant 
strategy, as additional effects are combined with considerable cost savings. The 
sensitivity analyses suggest that results were mostly driven by drug-specific clini-
cal effects on SFD, inputs for immunotherapy discontinuation, and length of the 
pollen season. The predicted cost savings were driven by the difference in treat-
ment costs. cOnclusiOns: Oralair® is cost-effective relative to Grazax®in patients 
with grass pollen-induced AR in Germany. Findings are confirmed by extensive 
sensitivity analyses.
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PaRtially hyDRolyzED SERum PRotEin aS ComPaRED With a StanDaRD 
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Objectives: To evaluate the potential economic impact of the 100% whey-based 
partially hydrolyzed infant formula (PHF-W) in comparison with a cow’s milk stand-
ard formula (SF) in the prevention of atopic dermatitis (AD) in at-risk children at 
the age periods 0–12 and 0–36 months in Russia. MethOds: The Excel model was 
constructed to estimate costs of artificial feeding with PHF-W vs SF and expected 
AD cases treatment. The model was based on the results of meta-analysis of rand-
omized controlled trials (RCTs), literature data and the results of the expert survey. 
The costs of artificial feeding and AD treatment were calculated from the positions 
of different payers: health care system, family, and society as a whole. The incre-
mental cost-effectiveness ratio (ICER) per averted AD case was calculated for PHF-W 
vs SF. Results: From health care system point of view the use of PHF-W uniquely 
lead to cost savings. If we consider all costs from the societal perspective PHF-W 
vs SF requires additional costs in the first year of baby’s life, but in leads to cost 
savings in a 3-year horizon. From the perspective of the at-risk child’s family arti-
ficial feeding costs will increase from 266 to 408 Euro for PHF-W vs SF. However the 
likelihood of AD development in a child will decrease from 15 to 8% in the first year 
and from 27 to 19% over three years and accordingly this will prevent AD treatment 
costs. cOnclusiOns: Using PHF-W for the AD preventionin high-risk children have 
benefits for both the health system and for individual family.
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Objectives: In France, continuous positive airway pressure (CPAP) is recom-
mended as first-line treatment for patients with severe OSAHS or mild-to-mod-
erate OSAHS with high cardiovascular risk. Dental devices are recommended 
as second-line treatment for these patients and can be suggested as first-line 
treatment for mild-to-moderate OSAHS patients without high cardiovascular 
risk. Lifestyle advice is recommended for overweight patients. This study aims to 
assess the cost-effectiveness of these treatments for mild-to-moderate OSAHS 
patients. MethOds: This study was commissioned by the French National 
Authority for Health (HAS) and followed their recommendations. A Markov model 
was developed to simulate the lifetime progression of a cohort of mild-to-mod-
erate adult OSAHS patients. CPAP was compared with dental devices, lifestyle 
advice and no treatment. Daytime sleepiness, cardiovascular disease and road 
traffic accidents were taken into account. Clinical parameters were taken from 
international publications. Costs were retrieved from the French national health 
insurance databases: Assurance Maladie and Technical Agency of Information on 
